Randomized, Multicenter, Phase III, Open-label study of Alectinib Versus Crizotinib in Treatment-naive anaplastic lymphoma kinase-positive Advanced Non-small Cell Lung Cancer
A study for patients with advanced non-small cell lung cancer using study drug Alectinib
Sponsor: Hoffmann-La Roche
Enrolling: Male and Female Patients
IRB Number: AAAN9415
U.S. Govt. ID: NCT02075840
Contact: Ryan Shelton: 212-304-5485 / rs3323@columbia.edu
Additional Study Information: The purpose of this study is to compare the effects, good or bad, of drugs alectinib and crizotnib on patients with lung disease to find out which is better for patients with a special type of non-small cell lung cancer (NSCLC) that is called anaplastic lymphoma kinase (ALK)-positive NSCLC. In this study, participants will receive either alectinib or crizotnib. Study procedures also include, MRI scans, cancer tissue collections, blood and urine samples as well as other psychical examinations.
This study is closed
Sewanti Limaye, MD
Do You Qualify?
Have you had any prior treatment for advanced,recurrent or metastatic NSCLC? Yes No
You may be eligible for this study

Place Holder

For more information, please contact:
Ryan Shelton